Skip to content

Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus

Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00329524
Enrollment
5
Registered
2006-05-24
Start date
2006-06-30
Completion date
2008-08-31
Last updated
2015-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus

Keywords

Tinnitus, TMS, Transcranial Magnetic Stimulation

Brief summary

One out of every five people experience tinnitus (a buzzing, ringing, or roaring sound in the ear) ranging from mild to severe impairment. To date there is no effective therapy that seems to help the tinnitus sufferer. The purpose of this study is to develop a therapy using a technique called Repetitive Transcranial Magnetic Stimulation (rTMS) to hopefully alleviate or reduce the symptoms of tinnitus. This research is being conducted at the University of Arkansas for Medical Sciences (UAMS). Up to twenty (20) right handed subjects, either males or females, 19-65 years of age, with tinnitus that is severe enough for those persons to seek medical attention will have been seen as patients in the UAMS Hearing and Balance Center, where routine testing includes a physical exam, hearing tests, evaluation of middle ear status, and an MRI scan (a machine that acquires visual images of the brain). A diagnosis of tinnitus will be established after ruling out all other possible causes of the tinnitus.

Detailed description

Subjects will be up to 20 right-handed patients (men and women), 19-65 years of age, with debilitating unilateral or bilateral tinnitus. All subjects must report experiencing the presence of their phantom auditory perception for at least 6 months and have a Tinnitus Handicap Questionnaire (THQ) score \>30. Subjects will be recruited from the Otolaryngology Clinic at UAMS, where routine testing includes a physical exam; pure tone audiometry; and evaluation of middle ear status using tympanometry, stapedius reflex tests, and otoscopy. Patients will undergo a gadolinium-contrast MRI of the head to rule out acoustic neuroma or any other central nervous system pathology. All subjects will be thoroughly informed of the risks associated with the procedures in this study, as described in the Hazards to Subjects section, and written informed consent will be obtained. Subjects will be recruited for this study without regard to race or ethnicity.

Interventions

DEVICERepetitive Transcranial Magnetic Stimulation (rTMS)

TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.

Sponsors

Tinnitus Research Consortium
CollaboratorOTHER
University of Arkansas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* right-handed subjects * 19-65 years of age * debilitating unilaterial or bilateral tinnitus * Experiencing the presence of phantom auditory preception for \>6 months * Tinnitus Handicap Questionnaire score of \>30

Exclusion criteria

* significant neurological disease * acoustic neuromas or glomus tumors * active Meniere's disease * profound hearing loss * non English speaking * personal or family history of epilepsy * personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological or psychiatric disorders, metal implants in the head or neck, a pacemaker, pregnancy, migraines, * medications that lower seizure threshold and are contraindicated * individuals who have been taking certain medications * claustrophobia * patients who do not exhibit significant cortical asymmetries on PET

Design outcomes

Primary

MeasureTime frameDescription
Change in PET Asymmetry IndexAfter active treatment weekChange in calculated PET asymmetry index between left and right temporal lobe from baseline following active Tx

Secondary

MeasureTime frameDescription
Psychomotor VigilanceImmediately after treatmentChange in simple auditory reaction time after treatment
Difference in Visual Analog Rating of Tinnitus (VAR)Following Active and Sham Tximmediately following active and sham TMSRating of tinnitus loudness using a scale of 0-100 for

Countries

United States

Participant flow

Participants by arm

ArmCount
Active Versus Sham TMS
Active or sham TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging according to a randomized schedule. This area will then be targeted either for active treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days or sham treatment of the same duration.
5
Total5

Baseline characteristics

CharacteristicActive Versus Sham TMS
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
5 Participants
Age, Continuous50 years
STANDARD_DEVIATION 5.5
Region of Enrollment
United States
5 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 5
serious
Total, serious adverse events
0 / 5

Outcome results

Primary

Change in PET Asymmetry Index

Change in calculated PET asymmetry index between left and right temporal lobe from baseline following active Tx

Time frame: After active treatment week

ArmMeasureValue (MEAN)Dispersion
Active Versus Sham TMSChange in PET Asymmetry Index1.2 ratioStandard Deviation 2.3
Secondary

Difference in Visual Analog Rating of Tinnitus (VAR)Following Active and Sham Tx

Rating of tinnitus loudness using a scale of 0-100 for

Time frame: immediately following active and sham TMS

ArmMeasureValue (MEAN)Dispersion
Active Versus Sham TMSDifference in Visual Analog Rating of Tinnitus (VAR)Following Active and Sham Tx2.5 analog ratingStandard Deviation 1.2
p-value: 0.05test for order effect
Secondary

Psychomotor Vigilance

Change in simple auditory reaction time after treatment

Time frame: Immediately after treatment

Population: per protocol

ArmMeasureValue (MEAN)Dispersion
Active Versus Sham TMSPsychomotor Vigilance-30 millisecondsStandard Deviation 18.27
p-value: <0.05t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026